THE FLAMMER SERIES
PART V
NORMAL
TENSION GLAUCOMA
Introduction
For
generations of ophthalmologists, glaucoma was simply defined as a disease
characterized by high intraocular pressure (IOP). It was almost forgotten that
the eminent German ophthalmologist Albrecht von Graefe (1828-1870) already in
1857 - and thus just seven years after the invention of the ophthalmoscope
which made the hallmarks of the disease like the optic nerve head (ONH)
excavation finally visible to physicians - encountered a patient with that
characteristic damage but with an IOP that did not seem to be increased at all.
Today,
normal tension glaucoma (NTG) is a widely recognized disease though there are
still ongoing discussions on whether it is just a special form of primary
open-angle glaucoma (POAG) or whether it is a distinct clinical entity with its
very own pathogenetic risk factors and with clinical features different from
POAG. Professor Josef Flammer has over the years in his many contributions to
science strenghtened the latter point of view. No doubt: the observation of
patients suffering from glaucomatous optic neuropathy (GON) with an IOP within
the normal range challenges the traditional pathophysiological concept of
glaucoma solely based on elevated IOP.
A
number of studies have evaluated the prevalence of normal tension glaucoma -
formerly sometimes described by the term "low tension glaucoma" -
among the overall glaucoma population.There are marked epidemiological
differences between different ethnicities. NTG seems to be much more frequent
among Asians than among a European population or one of European heritage. In
the Beaver Dam Eye Study, for instance, the prevalence of NTG among glaucoma
patients (predominantly white individuals) was 32%, in the Rotterdam Study it
was 39%. It was higher among people of African heritage (who are more
susceptible to glaucoma in general than other groups) as demonstrated in a
study from Zululand where 57% of glaucoma patients had NTG. In Asia, however,
it dominates the POAG population: a study from Guangzhou, China, showed an NTG
prevalence of 85%; the highest NTG proportion ever reported was from Japan: 92%
of POAG patients.
Pathogenesis
and Risk Factors
Professor
Josef Flammer remembers quite well an experience he had as a young physician
who was doing a year-long residency at the eye clinic of the University of
British Columbia in Vancouver which at that time was the leading center
worldwide when it came to the management of glaucoma and research about its
causes. Not only did Flammer encounter patients with characteristic
glaucomatous damage at the ONH and the retinal nerve fibre layer (RNFL) while
having IOP within the normal range. His mentor and teacher, Professor Stephen
Drance, pointed to something that was peculiar about these patients: they often
had small hemorrhages at the rim of the optic disc. Drance was convinced that
this feature that today is widely regarded as a hallmark of NTG points to an
issue of the ocular perfusion - to be sure, POAG patients may have these
hemorrhages as well but they are about five times more frequent in individuals
suffering from normal tension glaucoma. Drance therefore ordered a routine
cardiovascular check-up for patients with NTG.
Professor
Flammer's research has established that the risk factors that lead to IOP
increase and thus to the "classical" version of glaucoma and those
that initiate GON are not identical but tend to be widely different. Risk
factors that lead to artherosclerosis are also risk factors that predispose to elevated
IOP like age, smoking, obesity, male gender, dislipidemia, diabetes mellitus,
systemic hypertension. NTG patients who show GON have, however, a very
different risk profile than "ocular hypertensives". Risk factors for
NTG include female gender, race (i.e. Asian heritage, see above) primary
vascular dysregulations (PVD) and low blood pressure. On average, NTG patients
tend to be younger than glaucoma patients with an elevated IOP.
Ocular
blood flow (OBF) tends to be reduced in glaucoma patients and particularly so
in NTG patients. An unstable OBF is supposed to be a major cause of
glaucomatous damage; OBF is also significantly more reduced in glaucoma
patients showing progression than in patients who do noz progress. Normal
tension glaucoma patients have a reduced autoregulation: these eyes lack the
capacity to properly ensure a stable blood supply which becomes critical when
PVD and low blood pressure lead to a diminished blood flow towards the ocular
structures.
It
has been demonstrated that even more damaging than a continuously low blood
pressure are irregularities in blood pressure, excessive "spikes" and
equally excessive drops. Sharp decreases - particularly at night - play a
pathogenetic role in many NTG patients. The same can unfortunately been said
sometimes about medical therapy to lower an increased blood pressure, therapy
usually initiated by a general practitioner or specialist in internal medicine.
These medications can lead to blood pressure reductions - again, particularly
during sleeping hours - that prove to be dangerous to an already compromised
OBF in an NTG patient. Some sleeping pills have also the unwanted effect of
lowering the blood pressure during sleep in susceptible patients.
Professor
Flammer and his co-workers have over the years developed a pathogenetic concept
of glaucoma based on the role of OBF and led to the discovery of Flammer
syndrome which supports the hypothesis of "glaucoma as a sick eye in a
sick [from a vascular point of view] body". Both OBF and Flammer syndrome
have been discussed earlier in this series. Suffice it here to say that
vascular factors like recurrent hypoxia due to increased vascular resistance or
PVD as well as the so called reperfusion injury (the damage done to cells that
have for some time been deprived of adequate blood flow and than sometimes
virtually "drown" in re-established OBF and in oxygen) lead to
oxidative stress and inflammation, resulting in damage to the retinal ganglion
cells, the astrocytes and other layers at the ONH and the RNFL.
A
possible link between NTG and general disease has been the focus of a number of
studies. There is so far no established significant association between NTG and
diabetes mellitus. There are indications of a link between NTG and obstructive
sleep apnea (OSA), both having a multifactorial pathogenesis in which recurrent
hypoxia obviously plays a major role.
Diagnosis
The
basic diagnostics in glaucoma management apply also for NTG patients - with one
probable exception: IOP readings are no reliable predictors of progression. For
diagnosis and to draw a line versus POAG, IOP should always be below 21 mm Hg
before we speak of normal tension glaucoma. It has to be kept in mind, though,
that this is a rather arbitrary boundary - we are dealing with a continuum, not
with a clear distinction between NTG and POAG. The lower the IOP value that is
associated with glaucomatous damage and/or with progression, the higher is the
likelihood of vascular factors as a primary pathogenetic mechanism.
Structural
and functional measurements are valuable in establishing the diagnosis and
performing controls. Like in other fields of ophthalmology, the advent and
incresing sophistication of OCT has improved the diagnosis of glaucoma in
general and of NTG in perticular. Dynamic retinal vessel analysis (DVA) may add
further valuable information on the status of the patient's ocular vasculature.
Measuring
retinal venous pressure (RVP) can point to NTG: it is more frequently increased
in these eyes than in POAG.
Therapy
In
general, therapy of NTG has much in common with therapy of POAG:
ophthalmologists try to lower the patient's IOP as good as they can. IOP
reduction improves the prognosis in all types of glaucoma. This can be done
pharmacologically, by laser treatment or with a surgical intervention.
Nevertheless, some patients are known to progress despite an IOP level regarded
as appropriate ("target pressure") has been reached.
In
NTG patients in which OBF seems to be a major factor, other treatment options
in addition to IOP lowering have been tried to achieve functional stability and
to prevent further progression. Since low blood pressure is common among NTG
patients, further reductions should be prevented or, in some cases, even
raising the blood pressure moderately will be tried. This requires a close
cooperation between ophthalmologist and general practitioner or internal
medicine specialist or cardiologist - the latter disciplines are traditionally
concerned with lowering blood pressure, not elevating it. In daily practice,
informing these colleagues about the dangers of low blood pressure in NTG
patients and convincing them to stabilize blood pressure at a somewhat higher
level as well as avoiding fluctuations has often proven to be quite a challenge
for ophthalmologists.
In
Basel, Professor Flammer and his team have been able to improve vascular
regulation locally by carbonic anhydrase inhibitors and systemically with low
dose magnesium and low dose calcium channel blockers. Evening eals with a
higher-than-average dose of salt can be helpful in preventing nighttime blood
pressure dips. Oxidative stress can potentially be reduced by gingko biloba.
The elucidation of IOP-independent risk factors will most likely add
therapeutic options in the future - and will challenge the in many places
still-dominant concept of glaucoma therapy: IOP reduction alone.
AUTHOR
Ronald D. Gerste, born in Magdeburg,
Germany, grew up and studied medicine (M.D.) and history (Ph.D.) at the University
of Düsseldorf, Germany. He has worked as an ophthalmologist, but over the years
moved to the field of medical publishing. Work for a number of journals and
publishers, based since 2001 near Washington DC where he is acting as a science
correspondent. Have the privilege of being associated with and a friend of
Prof. Flammer for more than 20 years; was part of the team that translated his
great book "Glaucoma" into the English language. He has written
repeatedly on Flammer Syndrome in German-language journals. Also the publicist
for the Swiss Academy of Ophthalmology (SAoO), the German Society for Cataract
and Refractive Surgery (DGII) and the German Glaucoma Awareness Association
(Initiativkreis Glaukom).
This comment has been removed by the author.
ReplyDeleteThere are steps to diagnosis glaucoma problem in eyes. After putting drops in eyes to dilate the pupil doctor examine your eyes. And check the optic nerve to check the pressure on it or if any sign of glaucoma.
ReplyDeleteGlaucoma is a disease of eye which have certain causes, symptoms and treatment.
ReplyDeleteIf glaucoma is not treated, vision loss might continue, leading to complete blindness over time. Everyone should consult a <a href="https://thesightavenue.com/glaucoma-services/> Glaucoma Specialist </a> for more info.
ReplyDeleteHey thегe and Thank you so much for sharing this information. It has very useful. Please keep sharing.If you want more about the best treatment for glaucoma Kindly click the link best glaucoma specialistin coimbatore
ReplyDelete